PubMed Health⌕ Search

Biomedical subjects

N Arisato

Publications and source records attributed to N Arisato.

3 recordsLinked to original sources

Determination of antigenic epitopes recognized by four monoclonal antibodies to glutathione S-transferase pi (GST-pi).

Four independent antibodies (6A, 5F, 2H and 2F) to Glutathione S-transferase pi (GST-pi) were selected to characterize their epitopes. Amino acid analysis of 5.6 K and 7.4 K tryptic peptides appeared to suggest that the epitope recognized by antibodies 2H and 2F is located in the N-terminal 44 peptides of GST-pi, and that of 6A and 5F is located in the C-terminal 69 peptides. Reactivities of antibodies 6A and 5F with two synthetic peptides indicated that 6A recognized an epitope in the C-terminal hydrophilic fragment 176Leu-209Gln, and could be distinguished from 5F which recognized an epitope in the 141Thr-176Leu hydrophobic fragment. The differential immuno-reactivity of antibodies 6A and 5F with GST-pi itself, was characterized by the particularly high reactivity of 6A and almost no reactivity of 5F with the natural conformation of GST-pi in solution. This may be explained by differences in the hydropathic natures of their epitopes. The 6A antibody was useful for immunodetection of GST-pi in circulation, while 5F was found to be most suitable for histochemical staining of tumor tissue.

Amino Acid Sequence↗

Serum glutathione-S-transferase-pi as a tumor marker for gastrointestinal malignancies.

A glutathione-S-transferase-pi (GST-pi) immunoradiometric assay was devised as a potential marker for serodiagnosis of malignant disease. Elevated serum GST-pi levels were observed in patients with various gastrointestinal malignancies including gastric, esophageal, colonic, pancreatic, hepatocellular, and biliary tract cancers. Patients with benign gastrointestinal diseases had normal GST-pi, but some patients with chronic hepatitis and cirrhosis had slightly elevated levels. Over 80% of patients with Stage III or IV gastric cancer and even about 50% of those with Stage I and II had elevated serum GST-pi. After surgery serum GST-pi levels returned to normal. Resected stomach cancers were immunohistochemically positive for GST-pi. During chemotherapy of colonic, gastric, and hepatocellular cancers with a series of different drugs, GST-pi changed in a biphasic manner; increases during initial phases of therapy may reflect acquisition of drug resistance by the tumor. In general, serum GST-pi assays provide a sensitive and reliable marker for gastrointestinal malignancies.

Biomarkers, Tumor↗